Trial Profile
A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) Treatment of COVID-19 in an Outpatient Setting
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PINETREE
- Sponsors Gilead Sciences
- 19 Apr 2023 Results of subgroup analysis assessing heterogeneity of treatment effect (HTE) of early outpatient remdesivir, focusing on time from symptom onset and number of baseline risk factors published in the Infectious Diseases and Therapy
- 22 Feb 2023 Results of analyzing Remdesivir Resistance in SARS-CoV-2 from the Phase 3 PINETREE ,presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 22 Feb 2023 Results assessing estimated dose exposure metrics of RDV and metabolites (GS-704277, GS-441524) in REDPINE (n=90) study compared to PINETREE (n=148) and REMDACTA(n=289) study participants presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023